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Background: Adiponectin Q is a hormone that modulates several metabolic processes and contributes to the
suppression of biochemical pathways leading to metabolic syndrome. Hence, polymorphic changes in the
adiponectin Q (ADIPOQ) gene are likely to contribute to metabolic disorders, and consequently lead to
atherosclerosis. In the present study, we performed a population-based association study for 8 SNPs in 4646 Saudi
individuals (2339 CAD cases versus angiographed 2307 controls) by real-time PCR.
Methods: Linkage analysis was done by the Affymetrix Gene Chip array, sequencing by the MegaBACE DNA
analysis system and genotyping accomplished by TaqMan chemistry with the Applied Biosystem real-time Prism
7900HT Sequence Detection System.
Results: The rs2241766 (TG + GG) [Odds ratio(95% Confidence Interval = 1.35(1.01-1.72); p = 0.015] and rs9842733A > T
[1.48(1.01-2.07); p = 0.042] were associated with hypertension [HTN; 3541 cases vs 1101 controls), following
adjustment for the presence of other cardiovascular risk traits. The rs2241766 (TG + GG) was further implicated in
harbouring of low high density lipoprotein levels (LHDL; 1353 versus 2156 controls) [1.35(1.10-1.67); p = 0.005], but
lost its association with obesity after the adjustment for confounders. Besides, low high density lipoprotein was
also linked with rs6444174 (TC + CC) [1.28(1.05-1.59)]. On the other hand, while initial univariate logistic regression
analysis pointed to rs1063537 C > T (p = 0.010), rs2082940 C > T (p = 0.035) and rs1063539 G > C (p = 0.035) as
being associated with myocardial infarction, significance levels of these relationships were diminished following
adjustment for the influence of confounding covariates. Interestingly, haplotyping showed that an 8-mer
haplotype GTGCCTCA and several of its derivatives constructed from the studied SNPs were commonly implicated
in MI (χ2 = 4.12; p = 0.042), HTN (χ2 = 6.40; p = 0.011) and OBS (χ2 = 5.18; p = 0.023).
Conclusion: These results demonstrate that the ADIPOQ 3′UTR harbours common susceptibility variants for
metabolic risk traits and CAD, pointing to the importance of this region in atherosclerosis disease pathways.
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Metabolic syndrome (MS) relates to a cluster of risk fac-
tors for atherosclerosis and type 2 diabetes mellitus
(T2DM) comprising obesity, insulin resistance, hyper-
tension (HTN) and dyslipidemia [1,2]. Adiponectin is a
hormone that modulates several metabolic processes,
and is believed to play a significant role in the suppres-
sion of metabolic derangements that may trigger MS.
Hence, alterations in circulating adiponectin levels,
largely thought to be a consequence of changes in the
ADIPOQ gene sequence, constitute potential risk for dis-
orders such as obesity [2], insulin resistance [2,3], T2DM
[4,5], MS [3], and consequently susceptibility to acquir-
ing atherosclerosis. In particular, two single nucleotide
polymorphisms (SNPs), the rs2241766 (+45 T > G) and
rs266729 (−11377C > G), among others, have been ex-
tensively discussed as important determinants of total
adiponectin levels [5,6], as well as risk for T2DM [5,7],
MS [3,8], obesity [8] and coronary artery disease (CAD)/
myocardial infarction (MI) [9-12] in different ethnic
populations. On the other hand, available literature on
the role of the adiponectin gene (ADIPOQ) in athero-
sclerosis remains inconsistent. Thus, while some studies
suggest a causative role for the gene [9,11-14], these
findings have often turned out to be partly nonreplicable
or disputable [15,16]. Hence, the essence of ADIPOQ as
cardiovascular risk and specifically, its involvement in
dyslipidaemia-related CAD onset has not been exhaust-
ively addressed yet. Furthermore, while it is now well ap-
preciated that early onset of CAD often manifests itself
in familial dyslipidaemic disorders such as familial
hypercholesterolemia (FH), the risk genes associated
with this phenomenon remain to be deciphered. Specif-
ically, the role of ADIPOQ in early onset CAD is still
not well-understood. In a preliminary genome-wide
linkage study involving a Saudi family consisting of 11
individuals, with predominant heterozygous familialS1             S2  D1    S3    S4 
Figure 1 The pedigree of the studied family. Red denotes the primary p
mother; S1-7, sons 1–7; D1-2, daughters 1 and 2.hypercholesterolemia (HFH), we identified using the
Affymetrix Gene Chip 250 sty1 mapping array, several
genomic loci that were linked to both early onset of
CAD and HFH (Additional file 1). These loci included
one on chromosome 3, which harbours the ADIPOQ
gene. Sequencing the gene in the family members and
200 individuals from the general population revealed the
ADIPOQ gene as being extensively polymorphic in the
Saudi population. This led to the notion of interactions
involving some of the metabolic risk traits and the
ADIPOQ gene as a triggering factor for both early and
late onset of atherosclerosis. Furthermore, it is becoming
increasingly apparent that polymorphic changes in the
flanking 5 and 3 prime untranslated regions (3′UTR) of
genes may exert significant influence on complex disease
pathways [17,18]. In this study, we therefore set out
to investigate the likelihood of some of the ADIPOQ
variants we identified in the initial linkage experiment,
conferring risk for cardiovascular and metabolic risk
traits, focusing particularly on the involvement of the
3′UTR of the gene.
Methods
Study population
The present study was performed in three parts. The ini-
tial part consisted of a linkage study on early onset of
CAD in a family of 11 in which heterozygous familial
hypercholesterolaemia (HFH) was rampant (Figure 1).
This study linked chromosome 3q to both CAD and
HFH (Figure 2). We elected to investigate the potential
the role of the ADIPOQ gene as the most likely candi-
date at this locus for the development of atherosclerosis
associated with the presence of metabolic risk traits in
the general population. In order to identify variants of
interest, we then sequenced the gene in the 11 family
members and 200 individuals randomly selected
from the general population. The population-based      S5      S6   S7     D2













Figure 2 GT console mapping indicating the position of
homozygosity at the ADIPOQ locus for the mother (MT), and
the four affected offsprings S3, S4, S6 and D2. FT, father, MT,
mother; S1-7, sons 1–7; D1 and 2, daughters 1 and 2.
Muiya et al. BMC Medical Genetics 2013, 14:127 Page 3 of 9
http://www.biomedcentral.com/1471-2350/14/127association study comprised 4646 (3045 males and 1601
females, mean age 60.3 ± 0.2 yr) angiographed individ-
uals recruited for the population-based study on the
various cardiovascular disease traits. Among these were
2339 CAD individuals (1789 males and 550 females,
mean age 60.3 ± 0.2 yr) with angiographically determined
narrowing of the coronary vessels by at least 50% serving
as the CAD patient group (Table 1). Overall exclusion
criteria were major cardiac rhythm disturbances, incap-
acitating or life-threatening illness, major psychiatric ill-
ness or substance abuse, history of cerebral vascular
disease, neurological disorder, and administration of psy-
chotropic medication. The control group (CON) con-
sisted of 2307 angiographed individuals (1257 males and
1050 females, mean age 50.4 ± 0.4 yr) undergoing sur-
gery for heart valvular diseases or those who may have
reported with chest pain, but were established to have
no significant coronary stenosis by angiography. Exclusioncriteria for this group were, among others, ailments such
as cancer, autoimmune disease, or any other disorders
likely to interfere with variables under investigation. In this
study population, cardiovascular risk traits for atheroscler-
osis, particularly HTN (n = 3541), T2DM (2559), obesity
(1589) and dyslipidaemia were rampant enough to warrant
independent association analyses (Table 1). Individual can-
didates were characterized as hypertensive if their systole/
diastole blood pressure was ≥140/90 Hg [19]. Obesity was
defined as having body mass index (BMI) of ≥30.0 kg/m2,
while overweight was considered as having a BMI greater
than or equal to 25 kg/m2 (but <30.0 kg/m2), according to
the World Health Organization [20]. T2DM was character-
ized by combinations of decreased insulin secretion and
sensitivity (also defined as insulin resistance) [21]. The
study candidates for T2DM fulfilled the World Health
Organization criteria [22] and the American Association
for Diabetes Guidelines [21,23-25] for the disease. This
study was performed in accordance with the regulations
laid down by the Institutional Ethics Committee, and in ac-
cordance with the principles of the Declaration of Helsinki
as well as Title 45, Part 46 of the U.S. Code of Federal
Regulation on Protection of Human Subjects. All partici-
pants signed an informed consent.Linkage analysis for early onset coronary artery disease
Five ml of peripheral blood was sampled in EDTA tubes
from each of the study individuals after obtaining their
written consent, and genomic DNA extracted from leu-
kocytes by the standard salt methods using PUREGENE
DNA isolation kit (Gentra system, Minneapolis, MN,
USA). Genome-wide scanning was performed using the
Affymetrix Gene Chip 250 sty1 mapping array (Affyme-
trix, Inc., Santa Clara, CA, USA). Briefly, 250 ng of gen-
omic DNA was digested with the restriction endonuclease
StyI, mixed with its adaptors and ligated with T4 DNA
ligase. The mixture was added to four separate PCR re-
actions, amplified, pooled and purified to remove the
unincorporated dNTPs. The PCR product was fragmen-
ted, biotinylated, hybridized to the 250 sty1 array for
18 h, washed, stained and scanned as recommended by
the manufacturer. SNP genotypes, linear chromosomal
locations and marker ordering were detected with the
Affymetrix GeneChip® Genotyping Analysis Software
(GTYPE) Version 4.0.
Multipoint parametric linkage analysis was performed
using the GeneHunter Easy Linkage analysis software
4.0 (Affymetrix, Inc., Santa Clara, CA, USA) for estimat-
ing the LOD scores. Both autosomal recessive and dom-
inant models of inheritance were tested in search of
chromosomal linkage regions, using Asian SNP allele
frequencies. Copy Number Analyzer for GeneChip®
(CNAG) Ver. 3.0 (Affymetrix, Inc., Santa Clara, CA,
Table 1 Demographics and clinical data of the studied patients
Controls Cases
All Male Female All Male Female
CAD 2307 1257(54.5) 1050(45.5) 2339 1789(76.5) 550(23.5)
MI 1640 826(50.4) 814(49.6) 3005 2220(73.9) 785(26.1)
FH 3735 2451(65.6) 1284(34.4) 911 595(65.3) 316(34.7)
T2DM 2086 1335(64.0) 751(36.0) 2559 1710(66.8) 849(33.2)
HTN 1101 729(66.2) 372(33.8) 3541 2313(65.3) 1228(34.7)
OBS 2472 1784(72.2) 688(27.8) 1589 880(55.4) 709(44.6)
lHDLC 2156 1244(57.7) 912(42.3) 1762 1353(76.8) 409(23.2)
hChol 2019 1306(64.7) 713(35.3) 2441 1615(66.2) 826(33.8)
hTG 2842 1834(64.5) 1008(35.5) 1094 778(71.1) 316(28.9)
Smokers 2768 1310(47.3) 1458(52.7) 1759 1684(95.7) 75(4.3)
Clinical characteristics (relative to coronary artery disease)
Age 50.4 ± 0.4 51.2 ± 0.5 49.8 ± 0.5 60.3 ±0.2 59.8 ± 0.3 61.8 ± 0.54
BMI 29.0 ±0.2 27.97 ± 0.2 30.3 ± 0.3 28.9 ± 0.1 28.3 ± 0.1 31.0 ± 0.3
Total Chol 4.51 ± 0.02 4.42 ± 0.03 4.62 ± 0.03 4.48 ± 0.02 4.43 ±0.03 4.66 ± 0.05
HDL-Chol 1.26 ±0.01 1.18 ±0.03 1.33 ±0.01 1.15 ±0.01 1.15 ± 0.01 1.25 ± 0.02
LDL-Chol 2.76 ± 0.02 2.73 ± 0.03 2.80 ±0.03 2.71 ±0.02 2.68 ± 0.02 2.84 ±0.06
TG 1.52 ± 0.02 1.60 ± 0.03 1.44 ± 0.03 1.78 ± 0.02 1.78 ± 0.03 1.78 ± 0.05
FG 6.87 ± 0.16 6.80 ± 0.23 6.92 ± 0.22 9.45 ± 0.31 9.27 ± 0.37 9.88 ± 0.56
BP 120/83 119/81 121/82 128/84 130/85 127/83
The numbers in brackets give the fraction of the total (all) values of the group. BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; Chol,
cholesterol; FG, fasting glucose; FH, family history of CAD; MI, myocardial infarction; TG, triglycerides; T2DM, type 2 diabetes mellitus; hLDLC, high low density
lipoprotein-cholesterol; hChol, hypercholesterolaemia; HDL, high density lipoprotein; hTG, hypertriglyceridaemia; HTN, hypertension; LDL, low density lipoprotein;
lHDLC, low high density lipoprotein-cholesterol; OBS, obesity.
Muiya et al. BMC Medical Genetics 2013, 14:127 Page 4 of 9
http://www.biomedcentral.com/1471-2350/14/127USA) was employed to check the shared chromosomal
regions for homozygosity.
Screening for ADIPOQ mutations
The ADIPOQ gene was sequenced using the MegaBACE
DNA analysis system (Amersham Biosciences, Sunnyvale,
CA, USA). Briefly, the DNA was subjected to PCR by
standard methods described elsewhere. Five μl of PCR
product were treated with 2 μl of ExoSAP-IT (USB
Corporation, Cleveland, Ohio, USA) at 37°C for 30 min
to allow the hydrolytic removal of excess primers and
dNTPs by Exonuclease 1 and Shrimp Alkaline Phosphat-
ase. The enzymes were inactivated at 80°C for 15 min, and
the sequencing reaction was initiated by mixing 2 μl DNA,
1 μl of 5 μmol primer, 8 μl of DYEnmic ET Dye
Terminator (Amersham Biosciences, Buckinghamshire,
UK) and 9 μl of distilled water. The mixture was
thermally cycled 40x at 95°C for 20 sec, 50°C for
15 sec, and 60°C for 1 min. Unincorporated dye-
labelled terminators were removed by gel-filtration
through the DyeEx 96 plate (Qiagen GmbH, Hilden,
Germany). The eluent was vacuum-dried and dissolved
in 10 μl of loading solution (GE Healthcare UK Ltd,
Little Chalfont, Buckinghamshire UK) for sequencing.Data were analyzed for SNPs by Lasergene software
(DNASTAR, Inc. Madison, WI, USA).
Association studies
Five ml of peripheral blood was sampled in EDTA tubes
from each of the study individuals after obtaining their writ-
ten consent, and genomic DNA extracted from leukocytes
by the standard salt methods using PUREGENE DNA isola-
tion kit (Gentra system, Minneapolis, MN, USA). Genotyp-
ing was achieved using the Taqman chemistry with the ABI
Prism 7900HT Sequence Detection System (ABI Inc.,
Foster City, CA, USA). Primers and the TaqMan fluoro-
genic probes bearing a suitable reporter dye on the 5′-end
and a quencher dye on the 3′-end were designed using
the Primer Express software V2.0 (ABI Inc., Foster City,
CA, USA) and procured from Applied Biosystems (ABI,
Warrington, UK). One probe was labeled with the VIC dye
and the other with the FAM dye at the 5′-end, and serial
dilutions were run to determine the optimal working con-
centrations. For each reaction, a 25 μl reaction mixture was
prepared from 5 μl containing 50 ng DNA, 12.5 μl of 2x
Universal mix (Eurogentec, Liege Science Park, Seraing,
Belgium), 1.25 μl of 20x probe assay mix and 6.25 μl
DNase-free distilled water. Three no-template controls
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sion signal. The first two cycles occurred at 50°C for 2 mi-
nutes, and 95°C for 10 min, followed by 40 amplification
cycles of 94°C for 15 sec, and 60°C for 30 sec. The plates
were then scanned for FRET signal using the 7900HT Se-
quence Detection system and data analyzed with SDS 2.4
software (ABI, Foster City, CA, USA).
Statistical analysis
The power calculation for the statistical validity of our
study population was calculated using the following
standard formula, n ¼ Z2p 1−pð Þ
d2
whereby Z is generally set
to 1.96, p is the conversion rate expected to be observed
(e.g. 0.7), and d represents the minimum absolute size
difference between the two groups. Using this formula,
we estimated that the sample size (n) required for our
study would be 323. In the present study, we employed a
population of 4646, which was large enough to produce
statistically meaningful interpretation of our results.
Comparison of genotypes and alleles between different
groups for continuous dependent variables was achieved
by Analysis of Variance (ANOVA) or Student’s test as
appropriate. Categorical variables were analyzed by Chi-
Square test. Univariate and multivariate logistic regres-
sion analyses were used to compute odds ratios and
their 95% confidence intervals, using the SPSS software
version 20 (SPSS Inc., Chicago, USA). The haplo.stats
package (http://mayoresearch.mayo.edu/mayo/research/
schaid_lab/software.cfm) in the R Statistical Computing
software (http://www.r-project.org/) was used to perform
haplotype-based association analysis. Significance of as-
sociation was determined between haplotypes and the
case–control status - a binomial trait denoting whether
or not a patient carried the disease. Odd ratios were cal-
culated using as reference the baseline haplotype
AGGAGAGA, and the Haplotype Score statistics for the
association of a haplotype with the binary traits calcu-
lated as in Schaid et al. [26] and Lake et al. [27],
whereby an association with a two-tailed p value <0.05
was considered statistically significant.
Results
Linkage analysis and gene sequencing
The sequencing of all exons, exon-intron junctions, the
promoter as well as the 3′-UTR of the ADIPOQ gene in
the HFH family members and 200 other individuals
from the general population led to the discovery of vari-
ous single nucleotide changes. The data was interrogated
against the HapMap (http://hapmap.org) and Perlegen
(http://genome.perlegen.com) databases to identify sin-
gle nucleotide polymorphisms (SNPs) of potential inter-
est. A total of 8 SNPs [rs2241766 (1), rs6444174 (2),
rs6773957 (3), rs1063537 (4), rs2082940 (5), rs4686804(6), rs1063539 (7) and rs9842733 (8)] were then selected
for further evaluation in the general population involving
4646 individuals. All of these SNPs reside in the 3′UTR,
except the rs2241766, found in exon 1 of the gene. This
SNP was included based on the inconsistency in current
literature discussing its potential impact as a cardiovas-
cular disease risk as well as the high prevalence of its
heterozygosity in our HFH study family.
Association studies
Adiponectin Q genotyping and cardiovascular risk traits
We first evaluated the relationship of the ADIPOQ vari-
ants with CAD/MI and its risk traits in our general popu-
lation. The clinical demographics of the studied patients
are given in Table 1. Two of the studies variants, the
rs2241766 (TG +GG) [Odds ratio(95% Confidence Inter-
val = 1.35(1.01-1.72); p = 0.015] and rs9842733A > T [1.48
(1.01-2.07); p = 0.042] were associated with hypertension
(HTN; 3541 cases vs 1101 controls), following adjustment
for the presence of other risk factors. The rs2241766 (TG+
GG) was further implicated in harbouring of low high
density lipoprotein levels (LHDL; 1762 versus 2156 con-
trols) [1.35(1.10-1.67); p = 0.005), but lost its association
with obesity after the adjustment. Besides, LHDL was
also linked with rs6444174 (TC + CC) [1.28(1.05-1.59).
However, while univariate logistic regression analysis
pointed to rs1063537 C > T (p = 0.010), rs2082940 C > T
(p = 0.035) and rs1063539 G > C (p = 0.035) as being
associated with myocardial infarction, the significance
of these relationships was lost following adjustment
for the influence of other covariates (Table 2 and
Additional file 1).
Adiponectin Q haplotyping and disease
Having established the sharing of a number of the ADIPOQ
variants by different disease traits, the next obvious stage
was to ascertain whether or not similar relationships for the
studied SNPs could be manifest at haplotype level. Thus,
we employed all the 8 studied SNPs to construct haplotypes
of potential interest (Figure 3). Accordingly, using the most
common 8-mer haplotype TTACCCCA (frequency = 0.344)
as baseline for the comparative analysis, we found several
haplotypes that were significantly associated with the vari-
ous disease traits, as listed in the ADIPOQ (Haplo Suppl
data, Additional file 2: Table S4, and summarized in
Table 3). Notably, by far the highest number of haplotypes
was linked to MI. These included the 8-mer GTGCCTCA
(χ2 = 4.13; p = 0.042) and several of its derivatives, such as
the 7-mer GTGCCTC (block 1–7; χ2 = 4.41; p = 0.036), the
6-mer GTGCCT (block 1–6; χ2 = 4.40; p = 0.036), the 5-
mer GTGCC (block 1–5; χ2 = 4.86; p = 0.028) as well as the
4-mer GTGC (block 1–4; χ2 = 5.06; p = 0.025) which were
equally involved in a causative fashion. In-depth analysis in-
dicated that the 4-mer haplotype GTGC, constructed from
Table 2 Adiponectin Q genotyping in cardiovascular disease traits in the general population
Variant Controls Cases Uncorr. B.(95% CI) Uncorr. P-value Corr. B.(95% C.I.) Corr. P-value
Hypertension
rs2241766 (TG + GG) 0.844 0.855 1.25(1.01–1.56) 0.039* 1.35(1.01–1.72) 0.015*
rs9842733 T 0.019 0.028 1.44(1.03–2.01) 0.031* 1.48(1.01–2.07) 0.042*
Myocardial Infarction
rs1063537 T 0.165 0.186 1.16(1.04–1.30) 0.010** 1.16(1.04–1.30) 0.070
rs2082940 T 0.206 0.225 1.12(1.01–1.24) 0.035* 1.11(0.98–1.26) 0.102
rs1063539 C 0.176 0.194 1.13(1.01–1.20) 0.035* 1.13(1.01–1.20 0.091
Hypercholestrolaemia
rs9842733 T 0.023 0.030 1.32(1.01–1.72) 0.043* 1.38(0.97–1.69) 0.085
Low HDL-Cholesterol
rs6444174 (TC + CC) 0.848 0.855 1.23(1.08–1.49) 0.042* 1.28(1.05–1.59) 0.016*
rs2241766 (TG + GG) 0.847 0.858 1.32(1.06–1.59) 0.013* 1.35(1.10–1.67) 0.005***
Obesity
rs2241766 (TG + GG) 0.848 0.858 1.27(0.96–1.54) 0.028* 1.61(0.99–1.54) 0.67
The table lists the variants associated with the hypertension (3541 cases vs 1101 controls), myocardial infarction (3005 vs 1640), obesity (1589 vs 2472),
hypercholesterolaemia (2441 vs 2019) and low high density lipoprotein (1762 vs 2156) among the 4646 studied individuals before and following adjustments for
the influences of other risks factors. Bonferroni corrections for age, sex and family history was performed for all studied variables, while inclusion of the individual
disease traits into the multivariate analysis varied dependent on the primary study case group. B, Coefficient; C.I., confidence interval; Uncorr. P-value; uncorrected
P-value; Corr. P-value; the adjusted P-values for the associations in presence of other factors. *P < 0.05, **P < 0.01, ***P < 0.005 by χ2 test.
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core for this relationship. Interestingly, apart from MI, the
same 8-mer haplotype GTGCCTCA also conferred risk for
HTN (χ2 = 6.40; p = 0.011) and obesity (χ2 =5.18; p = 0.023),
revealing a common causative genomic sequence for theseEx 1  Ex 2  Ex3    EX4          (3’-UTR)
Figure 3 Linkage disequilibrium structure of the eight studied
single nucleotide polymorphisms. Ex, exon; 3′-UTR, 3 prime
untranslated region; ADIPOQ, adiponectin Q gene; D’ = linkage
disequilibrium coefficient; r = regression coefficient.three important cardiovascular risks traits at the haplotype
level (Additional file 2: Table S6). Moreover, for the HTN
subset, it was the 7-mer GTGCCTC (block 1–7; χ2 = 7.17;
p = 0.007) and 6-mer GTGCCT (block 1–6; χ2 = 7.188; p =
0.007), constructed from the SNPs in the 3′UTR, which ex-
hibited the most significant relationship. Thus, this obser-
vation unequivocally demonstrates that the observed
changes in the 3′UTR are indeed crucial, not only at single
nucleotide, but also genomic sequence levels, in events
leading to these disease traits.
Interestingly, in contrast to the above traits, dyslipid-
aemic disorders were linked only to shorter haplotypes,
which were for the most part different from those impli-
cated in the other diseases. Thus, elevated cholesterol
levels were significantly associated with two sequences,
the 5-mer TTATT (χ2 = 9.56; p = 0.002) and its 4-mer
derivative TTAT (χ2 = 7.56; p = 0.006) involving the
SNPS rs2241766, rs6444174, rs6773957 and rs10635,
while LHDL levels were only linked to the 4-mer TCCA
(χ2 = 5.06; p = 0.025) (Table 3). It should also be men-
tioned that several protective haplotypes were partly
shared by the disease traits, including the 8-mer
GTGCCTCA and its derivatives, which were protective
against both HTN (χ2 = 6.40; p = 0.011) and obesity (χ2 =
5.18; p = 0.023). Further analysis also indicated that the
core for these protective properties was the complemen-
tary nucleotides of the same risk SNPs.
Discussion
The present study was designed to initially evaluate pos-
sible genomic linkage to early onset of CAD in HFH,
Table 3 Sharing of adiponectin Q haplotypes by cardiovascular risk traits
SNP block Haplotype Trait Pooled Controls Cases χ2 P-value
1-8 GTGCCTCA MI 0.025 0.022 0.029 4.13 0.042
HTN 0.025 0.021 0.029 6.40 0.011**
OBS 0.024 0.020 0.027 5.18 0.023*
1-7 GTGCCTC CAD 0.025 0.021 0.030 7.17 0.007**
MI 0.025 0.023 0.030 4.41 0.036
HTN 0.025 0.021 0.030 7.17 0.007**
OBS 0.025 0.020 0.028 6.19 0.013**
1-6 GTGCCT MI 0.025 0.023 0.030 4.40 0.036
HTN 0.025 0.021 0.030 7.19 0.007**
OBS 0.025 0.020 0.028 5.51 0.019**
1-5 GTGCC MI 0.027 0.025 0.032 4.86 0.028
HTN 0.027 0.023 0.032 6.46 0.011**
OBS 0.026 0.022 0.029 4.22 0.040
1-4 GTGC MI 0.028 0.025 0.033 5.06 0.025
HTN 0.028 0.023 0.032 6.60 0.010**
OBS 0.027 0.023 0.030 4.19 0.041
5-8 TCCA OBS 0.025 0.029 0.022 4.95 0.026
lHDL 0.025 0.021 0.029 5.06 0.025
The table lists some of the shared haplotypes constructed from the studied variants, rs224176 (1), rs6444174 (2), rs6773957 (3), rs1063537 (4), rs2082940 (5),
rs4686804 (6), rs1063539 (7) and rs9842733 (8), arranged sequentially by their chromosomal positions. The most frequent 8-mer haplotype TTACCCCA (0.344) was
employed as the baseline to determine the relative effects of these haplotypes. The pooled, control and case haplotype frequencies are proportions. SNP blocks
represent the range of variants constituting the respective haplotypes. CAD, coronary artery disease; MI, myocardial infarction; HTN, hypertension; OBS, obesity;
lHDL, low high density lipoprotein. *P < 0.02 and **P < 0.01 by χ2 test.
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loci implicated in both disorders. These loci included
one on chromosome 3, which harbours the ADIPOQ
gene, an attractive candidate for predisposing individuals
to cardiovascular disease. Ensuing sequencing of the
gene in the study family and general population revealed
several informative SNPs of potential interest, including
some residing in the 3′UTR of the gene. Hence, we
elected to focus primarily on the essence of genomic
changes in this region as a contributing factor to disease
pathways leading to the manifestation of atherosclerosis.
To begin with, three of the studied SNPs, rs1063537,
rs2082940 and rs1063539, appeared to be associated
with CAD/MI in the univariate analysis, albeit turning
non-significant in the presence of confounders, such as
age, gender, family history and other disease traits. How-
ever, at least two variants were associated with the de-
gree of atherosclerosis, indicating indeed that changes in
the AQIPOQ gene sequence pose a calculable risk for
the disease processes involved in the development of
atherosclerosis. To our knowledge, hardly any data exists
yet in the literature on the influence of these SNPs on
CAD/MI disease pathways, pointing to the novelty of
our present findings. Besides, although our study did
not identify any delineable relationship for four other
studied variants with CAD/MI per se, several otherinvestigations including some genome-wide association
studies have implicated these SNPs as well as the
AQIPOQ locus in general, in the disease [12,14,28].
Thus, our results furnish support to the notion of the
ADIPOQ as a risk gene for atherosclerotic processes.
Perhaps one of the most well-studied among these
SNPs is the rs2241766 (+45 T > G), which has been asso-
ciated with CAD/MI in different ethnic groups, includ-
ing the Iranian and Chinese Han populations [11].
Interestingly, our study also established significant cor-
relation for this SNP with HTN and the harbouring of
LHDL-cholesterol levels, adding weight to the notion of
common loci in this genomic region as an underlying
cause for these atherosclerosis risk traits. The fact that
this SNP was associated not only with these two dis-
eases, but also weakly implicated in obesity, strengthens
the notion of its candidacy as a risk factor for these im-
portant cardiovascular risk traits in our population. In
fact, its relationship with MI turned significant within
these disease subsets, except obesity, suggesting a con-
tributory component of these traits on the influence of
this genic change on atherosclerotic disease pathways.
Notably, this variant has also been associated with ele-
vated serum adiponectin levels in the Finnish and Thai
populations [5,29]. However, the influence of the
rs2241766 on these different disease traits or changes in
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of individual studies as well as meta-analyses [15,16].
This scenario points to potential ethnic differences in
the way this variant influences these disease traits. In-
deed, gender, ethnicity and classical confounders have
been suggested as accounting for some differences in the
observed relationships of some of the various ADIPOQ
variants with disease or elevation in its protein serum
levels. Thus, for example, the rs2241766 has been impli-
cated in higher body mass index (BMI) in absence of al-
terations in blood lipids, blood pressure or obesity in
Iranian females, leading to the notion of gender-selective
effect of the genotypes on BMI [30]. It is also worth
mentioning that the rs2241766 constitutes a silent poly-
morphism, which would suggest that no change in pro-
tein function is linked to it. However, it has been
suggested recently that many organs possess the ability
to selectively use certain codons for translational stabil-
ity, transcriptional selection, RNA stability, or protein
hydropathy, for example [31,32]. Hence, the finding of
an association of this SNP with disease in this and other
studies seems to point to the essence of this genomic
locus with respect to such regulatory mechanisms.
Amazingly, the sharing of causative entities was mani-
fest not only at SNP, but also at haplotype level, whereby
several 8-mers constructed from all the studied SNPs as
well as their derivatives conferred risk for the individual
disease traits. Moreover, the significance levels for some
of the haplotype relationships were much greater than
those for the individual SNPs, pointing to the strength
of haplotyping versus genotyping as a more robust indi-
cator for disease. Hence, our present observations raise
the all-important question as to whether or not there ex-
ists some form of ADIPOQ gene-disease trait interac-
tions paving the pathway(s) to atherosclerosis that are
related to these manifestations. Interestingly, in addition
to predicting the extent of the disease, the rs9842733 T
was also implicated in HTN and hChol, linking severity
of atherosclerosis with these important metabolic risk
traits at the level of single nucleotide alterations, intui-
tively providing further support for such a probability.
These findings therefore indicate that ADIPOQ poly-
morphism may offer some genetic explanation for com-
mon disease pathways associated with atherosclerosis.
Mechanistically, an important aspect of the present
study is that 7 of the 8 investigated SNPs reside in the 3′
UTR of the gene, and are invariably implicated in vari-
ous diseases traits predisposing individuals to athero-
sclerosis. Notably, exclusion of the rs2241766 from the
haplotype constructs did not alter the impact of the 7-
mer derivatives constructed from the 3′UTR variants,
pointing to a pivotal role for this genic region in our ob-
servations. These findings demonstrate the importance
of this region in pathways linking atherosclerosis with itsdisease risk traits. In this regard, it is increasingly ac-
knowledged that the 3′UTR region contains important
elements, such as micro RNAs, that are involved in gene
regulatory processes, such as mRNA maturation. While
our results do not warrant qualified speculation as to
what mechanisms may be involved, it can nonetheless
be concluded that defects in such processes may be im-
portant for gene-trait interactions leading to complex
disorders, such as atherosclerosis. In fact, the candidacy
of the 3′UTR as a genomic risk locus for atherosclerosis
remains to be exploited, and therefore our notion calls
for further studies of this subject.
Conclusions
Our study described the sharing of several ADIPOQ var-
iants by metabolic risk traits among themselves as well
as CAD/MI, in support of an important role for this
gene in atherosclerosis disease pathways. Most import-
ant, the results also point to the harbouring by the ADI-
POQ 3′UTR of important elements regulating common
atherosclerosis disease pathways.
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